Koosakulchai Vanlaya, Sangsupawanich Pasuree, Wantanaset Duangdee, Jessadapakorn Wipa, Jongvilaikasem Pondtip, Yuenyongviwat Araya
Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
World Allergy Organ J. 2021 Jul 9;14(7):100560. doi: 10.1016/j.waojou.2021.100560. eCollection 2021 Jul.
Previous studies have shown that direct oral provocation tests, without prior skin testing, in children having delayed onset, benign rashes to beta-lactam antibiotic is safe and effective. Although, this test is useful in confirming drug hypersensitivity reactions, there is no standard protocol recommendation of drug provocation tests. This study aimed to evaluate the safety of the direct oral provocation test, using the Amoxicillin-2-step-challenge without prior skin testing, in children with history of non-immediate reactions to amoxicillin.
The Amoxicillin-2-step-challenge protocol was performed in children with history of non-immediate reactions to amoxicillin. This protocol is composed of 2 doses of amoxicillin, with a 30-min interval; continued for a total of 5 days. All of the patients had not undergone skin testing before the oral provocation test.
This study included 54 children, having a median age of 6.6 years, with 70.4% being male. Amoxicillin and amoxicillin-clavulanic acid were reported as the culprit drug in 75.9% and 24.1%, respectively. The index reactions were maculopapular (MP) rash in 79.6% and delayed urticarial rash/angioedema in 20.4%. Five patients (9.3%) had a reaction during the provocation test, all of these patients had delayed urticaria and were treated with oral antihistamine. However, 1 patient developed a fever alongside an MP rash. Laboratory investigation for this patient showed increased atypical lymphocytes and liver enzymes elevation.
Direct oral provocation tests, using the Amoxicillin-2-step-challenge, without prior skin testing, revealed good, immediate safety for the diagnosis of amoxicillin hypersensitivity in children with history of non-immediate reactions to amoxicillin.
先前的研究表明,对于出现延迟发作的β-内酰胺类抗生素良性皮疹的儿童,在未进行皮肤试验的情况下直接进行口服激发试验是安全有效的。尽管该试验有助于确诊药物过敏反应,但目前尚无药物激发试验的标准方案推荐。本研究旨在评估在有阿莫西林非速发型反应病史的儿童中,使用阿莫西林两步激发试验且不进行预先皮肤试验的直接口服激发试验的安全性。
对有阿莫西林非速发型反应病史的儿童进行阿莫西林两步激发试验方案。该方案由两剂阿莫西林组成,间隔30分钟;共持续5天。所有患者在口服激发试验前均未进行皮肤试验。
本研究纳入54名儿童,中位年龄为6.6岁,男性占70.4%。分别有75.9%和24.1%的患者报告阿莫西林和阿莫西林-克拉维酸为可疑药物。指标反应中,79.6%为斑丘疹(MP)皮疹,20.4%为延迟性荨麻疹皮疹/血管性水肿。5名患者(9.3%)在激发试验期间出现反应,所有这些患者均出现延迟性荨麻疹,并接受口服抗组胺药治疗。然而,1名患者在出现MP皮疹的同时出现发热。对该患者的实验室检查显示非典型淋巴细胞增多和肝酶升高。
对于有阿莫西林非速发型反应病史的儿童,使用阿莫西林两步激发试验且不进行预先皮肤试验的直接口服激发试验,在诊断阿莫西林过敏方面显示出良好的即时安全性。